-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Biomedicine is one of the strategic emerging industries with great promise and prospect.
At present, China's biopharmaceutical industry is in an explosive stag.
According to data, the market size has increased from 186 billion yuan in 2016 to 202 347 billion yuan, and is expected to reach 428 billion yuan in 2021.At the same time, the number of small domestic biopharmaceutical companies is also increasing rapidly, and biopharmaceuticals continue to accelerate their listin.
In 2021, there will be 121 new listed companies in China's biopharmaceutical field, a year-on-year increase of over 75.
.
The outbreak of the biopharmaceutical industry has driven the pharmaceutical machine industry to welcome change.
Multiple market increments (Source: Pharmaceutical Network) Under the influence of a series of favorable policies, the biopharmaceutical industry has entered an outbreak perio.
At present, the country is still further developing the biopharmaceutical industr.
"Pharmaceutical Industry Development Plan" and "14th Five-Year Plan for Bioeconomic Development" and other documents point out the direction for the future high-quality development of the biopharmaceutical industr.
The industry expects that, influenced by many policies that are favorable to the development of the biomedical economy, China's strategic scientific and technological strength in the biological field will continue to grow, which will strongly support the high-quality development of the bioeconom.
At the same time, it is expected to accelerate the realization of the "14th Five-Year Plan for the Development of Biopharmaceutical Industry.
By 2025, the operating income of the biopharmaceutical industry will be guaranteed to reach 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth of 10.
the above goal.
For pharmaceutical companies, under this background, what they need to do is to seize the opportunity and take advantage of the trend to accelerate the building of national biotechnology strategic scientific and technological forces, accelerate the breakthrough of the bottleneck of bioeconomic development, and provide a strong impetus for promoting the high-quality development of the biopharmaceutical industr.
suppor.
The development of biopharmaceuticals continues to improve, and the pharmaceutical machinery industry welcomes more market increment.
As the main part of the production cost of biological drugs, with the continuous development of the biopharmaceutical industry, the industry believes that the development of China's pharmaceutical machinery industry will also be further accelerate.
.
According to relevant information, the gross profit rate of biological drugs is about 90%, and the cost accounts for about 10%, of which direct materials account for about 25%, direct labor accounts for about 15%, and manufacturing costs account for about 60.
It can be seen that the development of the biopharmaceutical industry is greatly affected by the status quo of the pharmaceutical machinery industr.
In fact, on May 10, China issued the "14th Five-Year Plan for Bioeconomic Development", which clearly stated that the supply chain guarantee level of high-end biomedical equipment will be enhance.
The industry believes that this is expected to bring benefits to leading companies with strength in the biomedical equipment industr.
It is understood that the upstream supply chain of biopharmaceuticals mainly includes raw materials (reagents, consumables), scientific research instruments/equipment, biotechnology support and related supporting services, and is the core basic link of biopharmaceutical enterprise R&D and productio.
At present, China's biopharmaceutical industry is in an explosive stag.
As the main part of the production cost of biopharmaceuticals, it will also drive the development of China's pharmaceutical machinery industry to a certain extent, bringing more market growth to pharmaceutical equipment companie.
However, it should be noted that the domestic pharmaceutical equipment market, especially high-end pharmaceutical machines, has long relied on imported manufacturers, and domestic pharmaceutical machine companies have little right to spea.
Therefore, in order to seize more market increments, local enterprises must continue to increase investment in innovation and research and development, improve the stability and technicality of key processes, and accelerate the transformation and upgrading from low-end to mid-to-high-en.
It is understood that in fact, in the field of biopharmaceutical equipment, many companies have already begun to deplo.
Rutoflon began to lay out the bioengineering track in 201 In 2021, the company also acquired Qianchun Biology and invested in Saipu, and gradually expanded to the downstream consumables/devices fiel.
From 2020 to 2021, the revenue of its bioengineering sector will increase by 220% and 3015%, respectively, and the proportion of revenue will reach 27% and 263%, respectivel.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
At present, China's biopharmaceutical industry is in an explosive stag.
According to data, the market size has increased from 186 billion yuan in 2016 to 202 347 billion yuan, and is expected to reach 428 billion yuan in 2021.At the same time, the number of small domestic biopharmaceutical companies is also increasing rapidly, and biopharmaceuticals continue to accelerate their listin.
In 2021, there will be 121 new listed companies in China's biopharmaceutical field, a year-on-year increase of over 75.
.
The outbreak of the biopharmaceutical industry has driven the pharmaceutical machine industry to welcome change.
Multiple market increments (Source: Pharmaceutical Network) Under the influence of a series of favorable policies, the biopharmaceutical industry has entered an outbreak perio.
At present, the country is still further developing the biopharmaceutical industr.
"Pharmaceutical Industry Development Plan" and "14th Five-Year Plan for Bioeconomic Development" and other documents point out the direction for the future high-quality development of the biopharmaceutical industr.
The industry expects that, influenced by many policies that are favorable to the development of the biomedical economy, China's strategic scientific and technological strength in the biological field will continue to grow, which will strongly support the high-quality development of the bioeconom.
At the same time, it is expected to accelerate the realization of the "14th Five-Year Plan for the Development of Biopharmaceutical Industry.
By 2025, the operating income of the biopharmaceutical industry will be guaranteed to reach 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth of 10.
the above goal.
For pharmaceutical companies, under this background, what they need to do is to seize the opportunity and take advantage of the trend to accelerate the building of national biotechnology strategic scientific and technological forces, accelerate the breakthrough of the bottleneck of bioeconomic development, and provide a strong impetus for promoting the high-quality development of the biopharmaceutical industr.
suppor.
The development of biopharmaceuticals continues to improve, and the pharmaceutical machinery industry welcomes more market increment.
As the main part of the production cost of biological drugs, with the continuous development of the biopharmaceutical industry, the industry believes that the development of China's pharmaceutical machinery industry will also be further accelerate.
.
According to relevant information, the gross profit rate of biological drugs is about 90%, and the cost accounts for about 10%, of which direct materials account for about 25%, direct labor accounts for about 15%, and manufacturing costs account for about 60.
It can be seen that the development of the biopharmaceutical industry is greatly affected by the status quo of the pharmaceutical machinery industr.
In fact, on May 10, China issued the "14th Five-Year Plan for Bioeconomic Development", which clearly stated that the supply chain guarantee level of high-end biomedical equipment will be enhance.
The industry believes that this is expected to bring benefits to leading companies with strength in the biomedical equipment industr.
It is understood that the upstream supply chain of biopharmaceuticals mainly includes raw materials (reagents, consumables), scientific research instruments/equipment, biotechnology support and related supporting services, and is the core basic link of biopharmaceutical enterprise R&D and productio.
At present, China's biopharmaceutical industry is in an explosive stag.
As the main part of the production cost of biopharmaceuticals, it will also drive the development of China's pharmaceutical machinery industry to a certain extent, bringing more market growth to pharmaceutical equipment companie.
However, it should be noted that the domestic pharmaceutical equipment market, especially high-end pharmaceutical machines, has long relied on imported manufacturers, and domestic pharmaceutical machine companies have little right to spea.
Therefore, in order to seize more market increments, local enterprises must continue to increase investment in innovation and research and development, improve the stability and technicality of key processes, and accelerate the transformation and upgrading from low-end to mid-to-high-en.
It is understood that in fact, in the field of biopharmaceutical equipment, many companies have already begun to deplo.
Rutoflon began to lay out the bioengineering track in 201 In 2021, the company also acquired Qianchun Biology and invested in Saipu, and gradually expanded to the downstream consumables/devices fiel.
From 2020 to 2021, the revenue of its bioengineering sector will increase by 220% and 3015%, respectively, and the proportion of revenue will reach 27% and 263%, respectivel.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
